Pilot study of fibroblast activation factor expression in recurrent/progressive pancreatic cancer and mesothelioma using [68Ga]Ga-Fibroblast Activation Protein Inhibitor (FAPI) -46 PET imaging.
Not Applicable
Recruiting
- Conditions
- mesotheliomapancreatic cancerCancer - Lung - MesotheliomaCancer - Pancreatic
- Registration Number
- ACTRN12623001078640
- Lead Sponsor
- Sir Charles Gairdner and Osborne Park Health Care Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1.Diagnosed with: pancreatic cancer which is locally advanced or recurrent/progressive disease or malignant pleural mesothelioma at initial diagnosis or suspected disease progression.
2.Referred for a clinical [18F]FDG PET/CT scan.
3.Male and females greater than 18 years old.
4.Able to provide informed consent and undergo study procedures
Exclusion Criteria
1.Currently receiving treatment for pancreatic cancer or mesothelioma (including chemotherapy, radiotherapy or immunotherapy)
2.Pregnant at the time of PET scans
3.Unable to provide informed consent
4.Unable to undergo study procedures
5.Other active neoplastic disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method